Navigation Links
Pharmacopeia Announces Senior Additions to Management Team
Date:9/11/2007

all aspects of alliance and independent chemistry research and preclinical chemical development from target identification to investigational new drug (IND) submission. Additionally, he will serve as a key participant in the leadership of all alliances.

Dr. Kimball most recently served as Vice President, Medicinal Chemistry at Lexicon Pharmaceuticals, where he successfully directed that company's chemistry effort to discover drug candidates in multiple therapeutic areas, several of which have entered clinical development. In that position, he built and oversaw a department of more than 70 scientists that executed broad- ranging activities including analytical, structural and computational, process and medicinal chemistry. Prior to Lexicon, Dr. Kimball spent nearly 20 years at Bristol-Myers Squibb Pharmaceutical Research Institute. In various research roles at BMS, he oversaw innovative drug discovery and development projects in the areas of cardiovascular disease and oncology.

"Having worked closely with David Kimball for nearly 20 years, I have first-hand knowledge of his exceptional skills as both a leader and as a scientist," said David Floyd, Ph.D., Pharmacopeia's Executive Vice President and Chief Scientific Officer. "David will be an enormous asset to Pharmacopeia as we continue to build our discovery and development pipeline."

ABOUT PHARMACOPEIA

Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing toward clinical validation, both independently and with partners. Pharmacopeia's most advanced internal program is a dual-acting angiotensin and endothelin receptor antagonist (DARA) for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Pharmacopeia's collaborative efforts have resulted in a portfolio that includes one partnered pr
'/>"/>

SOURCE Pharmacopeia
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. PM announces a new health care order for India
2. Ramdoss Announces Introduction of RCH-II
3. Britain Announces Third Transfusion Related Mad Cow Case
4. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
5. Tibet Announces the Dalai Lama’s Tour of South Americ
6. NHS announces further Cost cutting Measures
7. Indian PM Announces Of Setting Up India Study Center At Tashkent
8. PowderMed Announces Needle-Less Flu Vaccine
9. Malaysia Announces Prison term On People Donating HIV-Contaminated Blood
10. Australian Government Announces Survey To Tackle Childhood Obesity
11. New Zealand Announces 10-year Plan For Betterment Of Mental Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/26/2014)... can provide much-needed relief from the summer heat, but ... much chlorinated water, experts warn. Amid the splashing ... water in their mouth. Some kids may even take ... parents. Although swallowing a small amount of pool ... that ingesting too much can lead to chlorine poisoning ...
(Date:7/26/2014)... (PRWEB) July 26, 2014 As reported ... on July 23rd, new research by Palo Alto Networks ... rewrite their playbook, now focusing more on businesses and ... who have become increasingly wise to their tactics over ... and CEO/CTO, Joe Caruso, talks about the evolution of ...
(Date:7/26/2014)... Multiple sclerosis (MS), also known as ... disease in which the insulating covers of nerve ... damaged. This damage disrupts the ability of parts ... a wide range of signs and symptoms, including ... takes several forms, with new symptoms either occurring ...
(Date:7/26/2014)... Kentucky (PRWEB) July 26, 2014 ... on the playing field; however, concussions in ... injuries. The occupations with the highest risk of ... ,     Firefighters ,     Police officers , ... workers ,     Delivery personnel , ...
(Date:7/26/2014)... As the category creator and world ... Xoçai is to transform and improve ... chocolate products. One such unique element is XoVita™, ... and blueberries, an ingredient combination exclusive to Xoçai. ... in all of Xoçai products and provides a ...
Breaking Medicine News(10 mins):Health News:Don't Let Kids Drink Pool Water 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 2Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 3Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 4Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 5Health News:Businesses the New Target for Nigeria’s 419 Cyber-Scammers 6Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 2Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 3Health News:Multiple Sclerosis Therapeutics Clinical Trials Market Review H2 2014 Analysis Report Available at MarketOptimizer.org 4Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 2Health News:KORT Physical Therapists Take the Mystery Out of Identifying and Treating Workplace Head Injuries 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 2Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 3Health News:Xocai-Asia Japanese Distributors in Hachioji, Japan Sanction Local Single-Source-Chocolate Investigative Report: MXI-Corp-Asia Discloses Direct-Sales Compensation Plan 4
... help because of illnesses related to alcohol abuse seem to ... ,Current official statistics show that emergency wards in ... and emergencies caused due to drunkenness since 1997. ... also have doubled, reported NHS since 1997, accounting for more ...
... up for pricey wine appreciation classes to parse the subtle ... and the black currant// scent of a cabernet sauvignon. Just ... quickly help you become a modest oenophile. It’s up to ... ,A new study by Northwestern University researchers shows that the ...
... official journal of the American Neurological Association, examined brain ... devastated in FTD//. ,Von Economo neurons (VENs) ... evolved in a select group of socially complex species: ... Across species, VENs are localized to frontal brain regions ...
... reach for aspirin. What is giving researchers a headache ... whether there is another form on top of the long-known ... India seems to have solved this controversial puzzle: yes, there ... pure form. ,“The two crystalline forms of ...
... the risk to develop stroke than men, discovered a British study ... of blood to the brain or due to tiny blockages in ... who suffered strokes had 40% more chance to have a family ... chances in those women having mothers who also had a history ...
... finds that 95 percent of Americans have pre marital sex-sex ... American men //and women as far back as the 1940 ... spending hundreds of millions of dollars advising young adults to ... One official disagreed and opined that even if the programs ...
Cached Medicine News:Health News:Researchers Discover How We Differentiate Smells 2Health News:A Study Finds VENs Devastated in FTD 2Health News:Does Aspirin Crystallize? 2
(Date:7/24/2014)... 24, 2014  Restore Health, a leading personalized ... announced that it is now offering pharmacogenetics testing ... individual based upon their particular genetic makeup. Comprehensive ... interaction between a patient,s genetics and their entire ... to provide this new service to healthcare providers ...
(Date:7/24/2014)... , Germany , and ... -- , Exclusive global license ... for SF3B1 mutations, including next-generation sequencing (NGS) gene panels, ... to be targeted by new test, indicate favorable prognosis ... syndromes  QIAGEN sees potential for developing companion ...
(Date:7/24/2014)... CITY, Calif., July 24, 2014  Abaxis, Inc. (NasdaqGS: ... point-of-care blood analysis systems, today reported financial results for ... First quarter overview: , Revenues of $47.5 ... , Diluted EPS of $0.21, up 50% over last ... Medical market revenues of $7.2 million, up 20% over ...
Breaking Medicine Technology:Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 2Restore Health Launches Pharmacogenetic Testing, Enhancing Its Suite of Personalized Medicine Goods and Services 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 2QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 3QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 4QIAGEN Adds Promising Genomic Biomarkers for Assessing Prognosis in Treatment of Blood Cancers to Personalized Healthcare Pipeline 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 2Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 3Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 4Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 5Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 6Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 7Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 8Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 9Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 10Abaxis Reports Financial Performance for the First Quarter of Fiscal 2015 11
... Intercept Pharmaceuticals, Inc., has announced that its first-in-class farnesoid ... endpoint of improved insulin sensitization in a 6 week ... patients with nonalcoholic fatty liver disease (NAFLD). , By ... that a single oral daily dose of INT-747 statistically ...
... , ST. PAUL, Minn., Oct. 1 Algos Therapeutics ... today announces the selection of Dr. Ganesh Iyer as ... his new responsibilities immediately. , "We were incredibly fortunate ... Dr. Iyer to lead Algos," stated Gary Smaby, Algos ...
Cached Medicine Technology:Intercept Pharmaceuticals' FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease 2Algos Attracts CRO Veteran Dr. Ganesh Iyer as its New CEO 2
Stainless steel bone clamp....
Reduction Forceps with Points for precise reduction of bone fragments with minimal soft tissue contact....
Designed for proximal femoral elevation in total hip replacement or in other surgery with a similar need for bone manipulation....
Straight double action bone cutting rongeur....
Medicine Products: